Samsung Biologics to Acquire PolyPeptide for $1.8 Billion
Samsung Biologics has announced its acquisition of Swiss peptide manufacturer PolyPeptide Group in an all-cash deal valued at $1.81 billion. This strategic move expands Samsung Biologics' presence into the peptide market.
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (67/100)Sources
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal - Bloomberg.com
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal Bloomberg.com
Read full article →Samsung Biologics buys Swiss peptide maker for $1.8bn
PolyPeptide takeover is latest example of South Korean companies expanding abroad through acquisitions
Read full article →Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
Samsung Biologics acquires PolyPeptide Group for 2.7 trillion won ($1.8 billion)
Read full article →Samsung Biologics expands into peptides with $1.8b PolyPeptide deal
Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its multi-modality and global manufacturing capabilities. The transaction is expected to be completed by the end of this year to mark the biggest takeover in the history of Korea’s biopharmaceutical industry, according to the company, which is Korea’s leading contract development and manufacturing organization, or CDMO. As PolyPeptide's shares ar
By The Korea Herald
Read full article →
